Table 1.
Characteristics of studies evaluating efficacy and safety of DEX implant in White Dot Syndrome.
| Author (Year) | Design | Condition | Eyes (n) | DEX Injections (Time Interval Range) | Follow up (Months) | Main Outcomes | Complications |
|---|---|---|---|---|---|---|---|
| Miserocchi et al. (2017) [68] | Retrospective case series | Serpiginous Choroiditis | 8 | Single (5 eyes), Repeated (3 eyes; 5–8 months) | 18 | Stabilization of serpiginous lesions, Decrease in systemic corticosteroids | Transient IOP increase (3 eyes), Cataract progression (2 eyes) |
| Mora-Cantallops et al. (2019) [72] | Case report | Acute Posterior Multifocal Placoid Pigment Epitheliopathy | 1 | Single | 6 | Stabilization of inflammatory lesions, Increased BCVA | Transient IOP increase |
| Barnes et al. (2018) [71] | Retrospective case series | Acute Zonal Occult Outer Retinopathy | 6 | Single | 14–63 | Stabilization of inflammatory lesions, Increased BCVA | Transient IOP increase, Cataract progression |
| Walsh et al. (2017) [69] | Retrospective case series | Birdshot Chorioretinopathy | 6 | Single (2 eyes), Repeated (4 eyes; 4–6 months) | 12–36 | Stabilization of inflammatory lesions, Reduced macular edema, Increased BCVA | IOP increase (2 eyes) |
| Bajwa et al. (2018) [70] | Retrospective case series | Birdshot Chorioretinopathy | 6 | Single (2 eyes), Repeated (4 eyes; 4–6 months) | 12–36 | Stabilization of the disease (2 eyes), Increased BCVA | IOP increase (2 eyes), Cataract progression (3 eyes) |
DEX: Dexamethasone intravitreal implant, IOP: Intraocular pressure, BCVA: Best corrected visual acuity.